Botanical species · safety record

Murraya koenigii

The EFSA Compendium of Botanicals holds 10 constituent measurements and 1 adverse-effect record for Murraya koenigii. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Murraya koenigii (L.) Spreng

10Constituent measurements

1Safety records

7Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Leaves	Solvent extraction	0.12 Percent	HPLC with standard detection methods	Resolve DOI
Furanocoumarins	Seed	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Indole alkaloids	Roots and other underground parts	Solvent extraction	—	Unspecified	Resolve DOI
Myrcene	Leaves	Essential oil	≤ 2.1 Percent	GC-MS	Resolve DOI
Myrcene	Leaves	Essential oil	≥ 0.5 Percent	GC-MS	Resolve DOI
Phellopterin	Seed	Solvent extraction	0.00096 Percent	HPLC with standard detection methods	Resolve DOI
Alkaloids	Aerial part of plants	Solvent extraction	—	GC-MS	No resolvable identifier
Isosafrole	Leaves	Essential oil	4.4 Percent	GC-MS	No resolvable identifier
Saponins	Live plants	Solvent extraction	—	Phytochemical screening	No resolvable identifier
Tannins	Live plants	Solvent extraction	—	Phytochemical screening	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Digestive	Digestive	Aerial part of plants	Solvent extraction	—	In vitro	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Verma, Ram S., Chauhan, Amit., Padalia, Rajendra C., Jat, Sanjeev K., Thul, Sanjog., Sundaresan, Velusamy. Phytochemical Diversity of Murraya koenigii (L.) Spreng. from Western Himalaya . Chemistry & biodiversity, 2013, vol. 10, no. 4, p. 628-641. DOI
Worthley, Elmer G., Schott, C. Donald. Biologically-active compounds in some flowering plants. Life sciences, 1969, p. 225-238.
Adebajo, Adeleke C., Reisch, Johannes. Minor furocoumarins of Murraya koenigii. Fitoterapia, 2000, vol. 71, no. 3, p. 334-337. DOI
Benalla, W., Bellahcen, S., Bnouham, M. Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors. Current diabetes reviews, 2010, vol. 6, no. 4, p. 247-254. DOI
Salikutty, J., Peter, K. V., Divakaran, M., Peter, KV. Curry leaf. Handbook of herbs and spices, vol 1, 2nd edition, 2012, no. 227, p. 260-274.
Kong, Y.C., Ng, G.K.H., Wat, C.K.H., But, P.P.H. Pharmacognostic differentiation between murraya paniculata (l.) jack and murraya koenigii (l.) spreng. Pharmaceutical biology, 1986, vol. 24, no. 3, p. 167-170. DOI
Nakamura, Seikou., Nakashima, Souichi., Oda, Yoshimi., Yokota, Nami., Fujimoto, Katsuyoshi., Matsumoto, Takahiro., Ohta, Tomoe., Ogawa, Keiko., Maeda, Sayuri., Nishida, Shino., Matsuda, Hisashi., Yoshikawa, Masayuki. Alkaloids from Sri Lankan curry-leaf (Murraya koenigii) display melanogenesis inhibitory activity: Structures of karapinchamines A and B . Bioorganic & medicinal chemistry, 2013, vol. 21, no. 5, p. 1043-1049. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature